{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:37:09Z","timestamp":1788349029645,"version":"build-2803163510"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>5\u03b1-Reductase inhibitors (5ARIs) are widely used for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To review all the available data on the effect of 5ARIs on sexual function and assess whether 5ARIs increase the risk of sexual dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of the literature was conducted using the Medline, Embase, and Cochrane databases. The search was limited to articles published in English and up to October 2015. Article selection proceeded according to the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria. Data were analyzed using Stata 12.0. A fixed- or a random-effects model was used to calculate the overall combined risk estimates. Publication bias was assessed using Begg and Egger tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Sexual dysfunction, erectile dysfunction, and decreased libido.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After screening 493 articles, 17 randomized controlled trials with 17,494 patients were included. Nine studies evaluated the efficacy of 5ARIs in men with BPH. The other eight reported using 5ARIs in the treatment of men with AGA. The mean age of participants was 60.10 years across all studies. We included 10 trials (6,779 patients) on the efficacy and safety of finasteride, 4 trials (6,222 patients) on the safety and tolerability of dutasteride, and 3 trials (4,493 patients) using finasteride and dutasteride for AGA. The pooled relative risks for sexual dysfunction were 2.56 (95% CI = 1.48\u20134.42) in men with BPH and 1.21 (95% CI = 0.85\u20131.72) in men with AGA; those for erectile dysfunction were 1.55 (95% CI = 1.14\u20132.12) in men with BPH and 0.66 (95% CI = 0.20\u20132.25) in men with AGA; and those for decreased libido were 1.69 (95% CI = 1.03\u20132.79) in men with BPH and 1.16 (95% CI = 0.50\u20132.72) in men with AGA. Estimates of the total effects were generally consistent with the sensitivity analysis. No evidence of publication bias was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence from the randomized controlled trials suggested that 5ARIs were associated with increased adverse effects on sexual function in men with BPH compared with placebo. However, the association was not statistically significant in men with AGA. Well-designed randomized controlled trials are indicated to study further the mechanism and effects of 5ARIs on sexual function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2016.07.006","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T01:16:29Z","timestamp":1469754989000},"page":"1297-1310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Effect of 5\u03b1-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials"],"prefix":"10.1093","volume":"13","author":[{"given":"Luhao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawpong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology \u00a0 \u00a0 \u00a0 , Guangzhou, Guangdong , China"},{"name":"Minimally Invasive Surgery Center \u00a0 \u00a0 \u00a0 , Guangzhou, Guangdong , China"},{"name":"Guangdong Provincial Key Laboratory of Urology \u00a0 \u00a0 \u00a0 , Guangzhou, Guangdong , China"},{"name":"The First Affiliated Hospital of Guangzhou Medical University \u00a0 \u00a0 \u00a0 , Guangzhou, Guangdong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"2024032602350734000_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1527-3458.2006.00053.x","article-title":"A new look at the 5alpha-reductase inhibitor finasteride","volume":"12","author":"Finn","year":"2006","journal-title":"CNS Drug Rev"},{"key":"2024032602350734000_bib2","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602350734000_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJM199401133300208","article-title":"Finasteride","volume":"330","author":"Rittmaster","year":"1994","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group","volume":"327","author":"Gormley","year":"1992","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib5","first-page":"550","article-title":"The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia","volume":"41","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI116665","article-title":"Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression","volume":"92","author":"Thigpen","year":"1993","journal-title":"J Clin Invest"},{"key":"2024032602350734000_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/1523-1747.ep12317162","article-title":"Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin","volume":"105","author":"Thiboutot","year":"1995","journal-title":"J Invest Dermatol"},{"key":"2024032602350734000_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0009-9236(98)90054-6","article-title":"A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride","volume":"64","author":"Gisleskog","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2024032602350734000_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1046\/j.1365-2133.1998.02504.x","article-title":"Predominance of type I 5alpha-reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis)","volume":"139","author":"Sato","year":"1998","journal-title":"Br J Dermatol"},{"key":"2024032602350734000_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU guidelines on neurogenic lower urinary tract dysfunction","volume":"56","author":"Stohrer","year":"2009","journal-title":"Eur Urol"},{"key":"2024032602350734000_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"2024032602350734000_bib12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","article-title":"British Association of Dermatologists' guidelines for the management of alopecia areata 2012","volume":"166","author":"Messenger","year":"2012","journal-title":"Br J Dermatol"},{"key":"2024032602350734000_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1346-8138.2011.01361.x","article-title":"Guidelines for the management of androgenetic alopecia (2010)","volume":"39","author":"Tsuboi","year":"2012","journal-title":"J Dermatol"},{"key":"2024032602350734000_bib14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(02)80349-4","article-title":"The effect of finasteride in men with benign prostatic hyperplasia. 1992","volume":"167","author":"Gormley","year":"2002","journal-title":"J Urol"},{"key":"2024032602350734000_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1464-410X.1996.00091.x","article-title":"The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients","volume":"78","author":"Wilton","year":"1996","journal-title":"Br J Urol"},{"key":"2024032602350734000_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"2024032602350734000_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","article-title":"Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia","volume":"44","author":"Andriole","year":"2003","journal-title":"Eur Urol"},{"key":"2024032602350734000_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"2024032602350734000_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","article-title":"Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia","volume":"61","author":"Wessells","year":"2003","journal-title":"Urology"},{"key":"2024032602350734000_bib21","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study","volume":"155","author":"Nickel","year":"1996","journal-title":"CMAJ"},{"key":"2024032602350734000_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib25","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/jamadermatol.2014.1830","article-title":"Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects","volume":"150","author":"Irwig","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2024032602350734000_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.140.7.857","article-title":"Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia","volume":"140","author":"Tosti","year":"2004","journal-title":"Arch Dermatol"},{"key":"2024032602350734000_bib28","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2490-2-14","article-title":"Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials","volume":"2","author":"Edwards","year":"2002","journal-title":"BMC Urol"},{"key":"2024032602350734000_bib30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archdermatol.2010.256","article-title":"Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review","volume":"146","author":"Mella","year":"2010","journal-title":"Arch Dermatol"},{"key":"2024032602350734000_bib31","first-page":"CD006015","article-title":"Finasteride for benign prostatic hyperplasia","volume":"10","author":"Tacklind","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2024032602350734000_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.urology.2013.10.007","article-title":"Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients","volume":"83","author":"Wu","year":"2014","journal-title":"Urology"},{"key":"2024032602350734000_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/09546634.2013.813011","article-title":"The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride","volume":"25","author":"Gupta","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"2024032602350734000_bib34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2015.36","article-title":"Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis","volume":"151","author":"Belknap","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2024032602350734000_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024032602350734000_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0090-4295(99)80304-5","article-title":"A brief male sexual function inventory for urology","volume":"46","author":"O\u2019Leary","year":"1995","journal-title":"Urology"},{"key":"2024032602350734000_bib37","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2024032602350734000_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2024032602350734000_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024032602350734000_bib40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2024032602350734000_bib41","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"2024032602350734000_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"2024032602350734000_bib43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2024032602350734000_bib44","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0090-4295(03)00661-7","article-title":"Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia","volume":"62","author":"Roehrborn","year":"2003","journal-title":"Urology"},{"key":"2024032602350734000_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","article-title":"Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia","volume":"63","author":"Roehrborn","year":"2004","journal-title":"Urology"},{"key":"2024032602350734000_bib46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.pcan.4500911","article-title":"Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men","volume":"9","author":"Roehrborn","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2024032602350734000_bib47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","article-title":"Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia","volume":"46","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"2024032602350734000_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaad.2009.09.018","article-title":"Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study","volume":"63","author":"Eun","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia","volume":"70","author":"Gubelin","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(98)00094-6","article-title":"Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group","volume":"51","author":"Marberger","year":"1998","journal-title":"Urology"},{"key":"2024032602350734000_bib51","first-page":"555","article-title":"Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss","volume":"41","author":"Roberts","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib52","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0090-4295(02)01971-4","article-title":"Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia","volume":"60","author":"Vaughan","year":"2002","journal-title":"Urology"},{"key":"2024032602350734000_bib53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1365-2133.2000.03780.x","article-title":"Finasteride increases anagen hair in men with androgenetic alopecia","volume":"143","author":"Van Neste","year":"2000","journal-title":"Br J Dermatol"},{"key":"2024032602350734000_bib54","first-page":"247","article-title":"Finasteride in the treatment of Japanese men with male pattern hair loss","volume":"14","author":"Kawashima","year":"2004","journal-title":"Eur J Dermatol"},{"key":"2024032602350734000_bib55","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","article-title":"The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride","volume":"55","author":"Olsen","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2024032602350734000_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-2042.2009.02357.x","article-title":"Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia","volume":"16","author":"Tsukamoto","year":"2009","journal-title":"Int J Urol"},{"key":"2024032602350734000_bib57","doi-asserted-by":"crossref","first-page":"f2109","DOI":"10.1136\/bmj.f2109","article-title":"Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study","volume":"346","author":"Toren","year":"2013","journal-title":"BMJ"},{"key":"2024032602350734000_bib58","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.juro.2013.12.014","article-title":"Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy","volume":"191","author":"Fwu","year":"2014","journal-title":"J Urol"},{"key":"2024032602350734000_bib59","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-2133.1999.03042.x","article-title":"Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp","volume":"141","author":"Bayne","year":"1999","journal-title":"Br J Dermatol"},{"key":"2024032602350734000_bib60","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.ju.0000097026.43866.cc","article-title":"Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia","volume":"171","author":"Roehrborn","year":"2004","journal-title":"J Urol"},{"key":"2024032602350734000_bib61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib62","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib63","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ecl.2007.03.004","article-title":"Androgenetic alopecia","volume":"36","author":"Otberg","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024032602350734000_bib64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0090-4295(98)00567-6","article-title":"Long-term effects of finasteride on prostate tissue composition","volume":"53","author":"Marks","year":"1999","journal-title":"Urology"},{"key":"2024032602350734000_bib65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4158\/EP12108.RA","article-title":"5alpha-reductases in human physiology: an unfolding story","volume":"18","author":"Traish","year":"2012","journal-title":"Endocr Pract"},{"key":"2024032602350734000_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/hmbci-2015-0015","article-title":"Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia","volume":"23","author":"Traish","year":"2015","journal-title":"Horm Mol Biol Clin Investig"},{"key":"2024032602350734000_bib67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2024032602350734000_bib68","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-4295(94)90068-X","article-title":"Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia","volume":"43","author":"Stoner","year":"1994","journal-title":"Urology"},{"key":"2024032602350734000_bib69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.urology.2004.04.084","article-title":"Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia","volume":"64","author":"Andriole","year":"2004","journal-title":"Urology"},{"key":"2024032602350734000_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"key":"2024032602350734000_bib71","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations","volume":"170","year":"2003","journal-title":"J Urol"},{"key":"2024032602350734000_bib72","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jsm.12525","article-title":"Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis","volume":"11","author":"Gacci","year":"2014","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib73","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cct.2007.07.008","article-title":"Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design","volume":"28","author":"Siami","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"2024032602350734000_bib74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"key":"2024032602350734000_bib75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/jsm.12368","article-title":"Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial","volume":"11","author":"Juang","year":"2014","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib76","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/db14-0249","article-title":"5alpha-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents","volume":"64","author":"Livingstone","year":"2015","journal-title":"Diabetes"},{"key":"2024032602350734000_bib77","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40618-015-0263-1","article-title":"5alpha-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia","volume":"38","author":"Chou","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"2024032602350734000_bib78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cen.12599","article-title":"A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia","volume":"82","author":"Lin","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024032602350734000_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"2024032602350734000_bib80","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2010.10.040","article-title":"Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial","volume":"59","author":"Roehrborn","year":"2011","journal-title":"Eur Urol"},{"key":"2024032602350734000_bib81","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1111\/j.1743-6109.2011.02425.x","article-title":"The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function","volume":"8","author":"Pinsky","year":"2011","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib82","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-5347(01)65062-6","article-title":"Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes","volume":"157","author":"Morales","year":"1997","journal-title":"J Urol"},{"key":"2024032602350734000_bib83","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0090-4295(01)01226-2","article-title":"Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction","volume":"58","author":"Becker","year":"2001","journal-title":"Urology"},{"key":"2024032602350734000_bib84","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1464-410x.1999.00913.x","article-title":"Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum","volume":"83","author":"Park","year":"1999","journal-title":"BJU Int"},{"key":"2024032602350734000_bib85","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.2174\/138161205774913408","article-title":"Sonic hedgehog, the penis and erectile dysfunction: a review of sonic hedgehog signaling in the penis","volume":"11","author":"Podlasek","year":"2005","journal-title":"Curr Pharm Des"},{"key":"2024032602350734000_bib86","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1743-6109.2012.02759.x","article-title":"Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy","volume":"9","author":"Oztekin","year":"2012","journal-title":"J Sex Med"},{"key":"2024032602350734000_bib87","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1743-6109.2012.02661.x","article-title":"Effects of oral finasteride on erectile function in a rat model","volume":"9","author":"Zhang","year":"2012","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516303149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609516303149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/9\/1297\/48194628\/jsm_13_9_1297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/9\/1297\/48194628\/jsm_13_9_1297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T22:53:33Z","timestamp":1711407213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/13\/9\/1297\/6940473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":87,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,1]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.07.006","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,9]]},"published":{"date-parts":[[2016,9,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 5\u03b1-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}